References
- Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97–107.
- Li HQ, Li Z, Liu Y, et al Association of polymorphism of tumor necrosis factor-alpha gene promoter region with outcome of hepatitis B virus infection. World J Gastroenterol 2005; 11: 5213–7.
- Lok AS, Lai CL, Wu PC, Wong VC, Yeoh EK, Lin HJ. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 1987; 126: 492–9.
- Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45: 507–39.
- McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009; 3: 334–42.
- Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB. Cloning and expression in Escherichia coli of the gene for human tumor necrosis factor. Nature 1986; 313: 803–6.
- Biermer M, Puro R, Schneider RJ. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-kappaB. J Virol 2003; 77: 4033–42.
- Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-$132#tumor necrosis factor-alpha therapy. J Rheumatol 2009; 36: 2416–20.
- Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009; 36: 1188–94.
- Hösel M, Quasdorff M, Wiegmann K, et al Not interferon, but interleukin–6 controls early gene expression in hepatitis B virus infection. Hepatology 2009; 50: 1773–82.
- Zou Y, Chen T, Han M, et al Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J Immunol 2010; 184: 466–75.
- Huizinga TW, Westendorp RG, Bollen EL, et al TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997; 72: 149–$132#53.
- Pociot F, D'Alfonso S, Compasso S, Scorza R, Richiardi PM. Functional analysis of a new polymorphism in the human TNF alpha gene promoter. Scand J Immunol 1995; 42: 501–4.
- Chinese Society of Liver Cancer, Chinese Anti-Cancer Association. The criteria of clinical diagnosis and different stage of primary hepatocellular carcinoma. Chin J Hepatol 2001; 9: 324.
- Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4: 314–20.
- Li X, Magenheimer BS, Xia S, et al A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nature Med 2008; 14: 863–8.
- Kim YJ, Lee HS, Yoon JH, et al Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003; 12: 2541–6.
- García-Ruiz C, Colell A, Marí M, et al Defective TNF-α-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J Clin Invest 2003; 111: 197–208.
- Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, Lai MM. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol 2006; 80: 7199–207.
- Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195–9.
- Fong CL, Mark DF. The NF-kappa B-like site in the TNF-alpha repressor element is essential for its repressor function. Biochem Biophys Res Commun 1995; 212: 879–86.
- Li C, Zhi-Xin C, Li-Juan Z, Chen P, Xiao-Zhong W. The association between cytokine gene polymorphisms and the outcomes of chronic HBV infection. Hepatol Res 2006; 36: 158–66.
- Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 1999; 66: 562–6.
- Jeng JE, Tsai HR, Chuang LY, et al Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma. Medicine (Baltimore) 2009; 88: 349–57.
- Baan R, Straif K, Grosse Y, et al WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of alcoholic beverages. Lancet Oncol 2007; 8: 292–3.
- Kuper H, Tzonou A, Kaklamani E, et al Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85: 498–502.
- Ogimoto I, Shibata A, Kurozawa Y, et al Japan Collaborative Cohort Study Group. Risk of death due to hepatocellular carcinoma among drinkers and ex-drinkers. Univariate analysis of JACC study data. Kurume Med J 2004; 51: 59–70.
- El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–76.
- Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-αlpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat 2007; 14: 841–8.
- Niro GA, Fontana R, Gioffreda D, et al Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int 2005; 25: 1175–81.
- Du T, Guo XH, Zhu XL, et al Association of TNF-αlpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population. J Viral Hepat 2006; 13: 618–624.